Why the study?
Does isradipine reduce 24-hour ambulatory blood pressure in male patients with mild essential hypertension?
Does isradipine reduce 24-hour ambulatory blood pressure in male patients with mild essential hypertension?
Isradipine monotherapy significantly reduces 24-hour ambulatory blood pressure and blood pressure spikes in men with mild essential hypertension.
Answers are grounded in this paper and cite their sources.
Supports isradipine monotherapy in mild hypertension; extends RCT evidence on ambulatory BP endpoints.
The hypotensive effect of isradipine was assessed in 26 male patients, aged 40 to 64 years, with hypertension. After withdrawal of previous antihypertensive treatment and a four-week placebo period, patients were randomized into a double-blind active-treatment period of eight weeks to receive either placebo or 1.25 to 2.5 mg isradipine twice daily. Twenty-four-hour ambulatory blood pressure was measured by Accutracker (Suntech, Oxford, England) after the placebo period and at the end of the active-treatment period. In the isradipine group n = 13), both systolic and diastolic blood pressure and number of blood pressure spikes decreased significantly (P less than .0001), whereas there was a significant increase of these variables in the placebo control group (n = 13). The results of this study indicate that, in these subjects, blood pressure control was achieved throughout the 24-h period by monotherapy with isradipine.
No takes yet. Share an insight, caveat, or question.
Viskoper et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: